Novo Nordisk A/S (NVO): FDA Schedules Advisory Committee Meeting For Liraglutide 3 Mg For The Treatment Of Obesity
5/21/2014 9:41:50 AM
BAGSVAERD, Denmark, May 20, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 11 September 2014 to discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of obesity. The NDA was submitted to the FDA on 20 December 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by